{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sibal PA"],"funding":["Japan Grant-in-Aid for Scientific Research","Takara Bio, Inc"],"pagination":["1259-1277"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11076993"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(5)"],"pubmed_abstract":["Oncolytic viruses (OVs) can selectively replicate in tumor cells and remodel the microenvironment of immunologically cold tumors, making them a promising strategy to evoke antitumor immunity. Similarly, agonists of the stimulator of interferon genes (STING)-interferon (IFN) pathway, the main cellular antiviral system, provide antitumor benefits by inducing the activation of dendritic cells (DC). Considering how the activation of the STING-IFN pathway could potentially inhibit OV replication, the use of STING agonists alongside OV therapy remains largely unexplored. Here, we explored the antitumor efficacy of combining an HSV-1-based OV, C-REV, with a membrane-impermeable STING agonist, 2'3'-GAMP. Our results demonstrated that tumor cells harbor a largely defective STING-IFN pathway, thereb"],"journal":["Molecular oncology"],"pubmed_title":["STING activator 2'3'-cGAMP enhanced HSV-1-based oncolytic viral therapy."],"pmcid":["PMC11076993"],"funding_grant_id":["18H02691","16H05413","16K15611"],"pubmed_authors":["Morimoto D","Eissa IR","Kasuya H","Ichinose T","Mukoyama N","Naoe Y","Sibal PA","Abdelmoneim M","Aboalela MAM","Matsumura S","Bustos-Villalobos I","Tanaka M"],"additional_accession":[]},"is_claimable":false,"name":"STING activator 2'3'-cGAMP enhanced HSV-1-based oncolytic viral therapy.","description":"Oncolytic viruses (OVs) can selectively replicate in tumor cells and remodel the microenvironment of immunologically cold tumors, making them a promising strategy to evoke antitumor immunity. Similarly, agonists of the stimulator of interferon genes (STING)-interferon (IFN) pathway, the main cellular antiviral system, provide antitumor benefits by inducing the activation of dendritic cells (DC). Considering how the activation of the STING-IFN pathway could potentially inhibit OV replication, the use of STING agonists alongside OV therapy remains largely unexplored. Here, we explored the antitumor efficacy of combining an HSV-1-based OV, C-REV, with a membrane-impermeable STING agonist, 2'3'-GAMP. Our results demonstrated that tumor cells harbor a largely defective STING-IFN pathway, thereb","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-01T23:43:05.718Z","creation":"2026-05-23T03:08:06.137Z"},"accession":"S-EPMC11076993","cross_references":{"pubmed":["38400597"],"doi":["10.1002/1878-0261.13603"]}}